Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.

Graybill WS, Vergote I, Pothuri B, Anttila M, O'Malley DM, Lorusso D, Haggerty AF, Fabbro M, Chan JK, Heitz F, Willmott LJ, Bruchim I, Zhuo Y, Estévez-García P, Monk BJ, Denys H, Knudsen A, Tinker AV, Sánchez LM, Provencher D, Barretina-Ginesta MP, Hartman J, Booth DV, González-Martín A

Open source

DOI: 10.57264/cer-2024-0133
Published: 2025 Jan
Container: Journal of comparative effectiveness research
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.57264/cer-2024-0133,
  title = {Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.},
  author = {Graybill WS and Vergote I and Pothuri B and Anttila M and O'Malley DM and Lorusso D and Haggerty AF and Fabbro M and Chan JK and Heitz F and Willmott LJ and Bruchim I and Zhuo Y and Estévez-García P and Monk BJ and Denys H and Knudsen A and Tinker AV and Sánchez LM and Provencher D and Barretina-Ginesta MP and Hartman J and Booth DV and González-Martín A},
  year = {2025},
  journal = {Journal of comparative effectiveness research},
  doi = {10.57264/cer-2024-0133},
  url = {https://doi.org/10.57264/cer-2024-0133}
}

RIS

TY  - JOUR
TI  - Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.
AU  - Graybill WS
AU  - Vergote I
AU  - Pothuri B
AU  - Anttila M
AU  - O'Malley DM
AU  - Lorusso D
AU  - Haggerty AF
AU  - Fabbro M
AU  - Chan JK
AU  - Heitz F
AU  - Willmott LJ
AU  - Bruchim I
AU  - Zhuo Y
AU  - Estévez-García P
AU  - Monk BJ
AU  - Denys H
AU  - Knudsen A
AU  - Tinker AV
AU  - Sánchez LM
AU  - Provencher D
AU  - Barretina-Ginesta MP
AU  - Hartman J
AU  - Booth DV
AU  - González-Martín A
PY  - 2025
JO  - Journal of comparative effectiveness research
DO  - 10.57264/cer-2024-0133
UR  - https://doi.org/10.57264/cer-2024-0133
ER  -

APA

WS, G., I, V., B, P., M, A., DM, O., D, L., AF, H., M, F., JK, C., F, H., LJ, W., I, B., Y, Z., P, E., BJ, M., H, D., A, K., AV, T., LM, S., D, P., MP, B., J, H., DV, B., & A, G. (2025). Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.. Journal of comparative effectiveness research. https://doi.org/10.57264/cer-2024-0133

Source records

pubmed · retrieved 2026-09-26T12:54:09.666Z